We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cancer Immunotherapy: Combination Therapy May Be the “Way of the Future”
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Cancer Immunotherapy: Combination Therapy May Be the “Way of the Future”
Medical InnovationsSpecialtiesTechnology

Cancer Immunotherapy: Combination Therapy May Be the “Way of the Future”

Deanna Pogorelc
Deanna Pogorelc
Share
4 Min Read
chemotherapy
SHARE

chemotherapyFirst published on MedCityNews.com. Efforts to overcome the unusual ability of cancer cells to dodge the body’s immune response have reached an inflection point this year.

chemotherapyFirst published on MedCityNews.com. Efforts to overcome the unusual ability of cancer cells to dodge the body’s immune response have reached an inflection point this year. And, at least according to some experts, commercial interest in cancer immunotherapies has gone through the roof.

“If you had asked most Big Pharmas in the beginning of 2013 if they were interested in immunotherapy, they would have said ‘not necessary, we’re (more) in small molecules,’” explained Marc Mansour, chief operating officer of Canadian vaccine developer Immunovaccine, in an interview last month.

But by the end of the American Society of Clinical Oncology’s annual conference this summer, the sentiment had shifted. Both Bristol-Myers Squibb and Merck presented solid early-stage data on their respective PD-1 inhibitors that added to excitement that’s been building over the past several years around immunotherapy.

More Read

VESAG Emergency Health Watch
6 Habits That Are Harmful To The Health Of Your Teeth
Diagnosing Illnesses with Advanced Technology
Support Critical When Treating Mental Health
Why Today’s Cancer Experts Love Educated Patients

Since then, AstraZeneca, for one, has added to its cancer portfolio of small molecule drugs and biologics with a $500 million buyout of Amplimmune in August. Bayer also signed an agreement with Compugen to research, develop and commercialize immunotherapies. Then there’s Roche, which signed deals with Inovio Pharmaceuticals and Germany’s immatics.

Both Bristol-Myers Squibb and Merck’s candidates are PD-1 inhibitors, which fall under an especially promising class of drugs being called immune checkpoint inhibitors.

“At least five or six pharmaceutical companies are conducting clinical trials on checkpoint inhibitors, and I think that we’re going to see approvals probably in the next year or two,” said Dr. James Gulley, director of medical oncology services at the National Cancer Institute’s Center for Cancer Research.

Bristol-Myers Squibb’s Yervoy, FDA approved in 2011 for treatment of melanoma, was the first checkpoint inhibitor on the market. A second generation of drugs in this area seem to be better tolerated but induce just as much immune activity, he said.

The real potential, though, lies in the ability of these inhibitors to be combined with other kinds of drugs, like vaccines. Gulley explained that vaccines – like the ones being developed my Immunovaccine, Merck, GSK and others – would act as the “gas” and the “steering” that would turn on the immune system and set its aim to fight cancerous cells. Then the checkpoint inhibitors would disable the “brake” – the body’s tendency to turn off the immune response once it’s killed the infected cells.

“Combination therapy is the way of the future,” Immunovaccine’s Mansour reiterated. For an upcoming phase 2 clinical trial in brain cancer, the company is pairing its vaccine candidate with temozolomide, an immune modulator that’s the standard therapy for newly diagnosed gliobastoma patients after surgery and radiation.

“But, it can’t be a $100K therapy on top of another $100K therapy,” he added. That’s one of the big industry takeaways from Dendreon’s Provenge, the first immunotherapy to be approved by the FDA back in 2010. The therapy, which requires a patient’s immune cells to be sent to a lab where they’re reprogrammed to attack cancer cells, and then sent back and injected back into the patient, has been met with weak sales that have forced the drugmaker to restructure.

“That’s not sustainable,” Mansour summed up. “We have to push to find therapies that work, and you have to think about it as a therapy rather than a compound.”

[Image credit: Flickr user Phil and Pam]

TAGGED:cancer
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare ethics-and-law training, shown through a coached clinical role-play where structured disc
Medical Ethics and the Law: The Training Behind Professionals Who Resolve Healthcare Disputes
Uncategorized
November 6, 2026
Flat editorial illustration: The article connects routine occupational health screening with early exposure detection and better
What Routine Workplace Health Monitoring in Medical Environments Actually Prevents
Uncategorized
November 6, 2026
Flat editorial illustration: The article contrasts structured prelicensure education with ongoing, practice-focused development f
Academic vs. Clinical Education: How Teaching Settings Shape Nursing Learners and Outcomes
Uncategorized
November 6, 2026
Flat editorial illustration: Health-editorial illustration of the two-way relationship between substance use and disrupted sleep,
How Sleep Disruption Feeds the Addiction Cycle and What You Can Do About It
Addiction Recovery Mental Health Wellness
November 6, 2026

You Might also Like

The Power of Meeting Another Patient

November 10, 2011
healthcare diagnostics research
DiagnosticsTechnology

New Medical Laboratories Are the Key to Diagnostics Research

January 18, 2021
woman with red lipstick smiling
Dental healthWilderness Medicine

7 Ways to Take Better Care of Sensitive Teeth

October 30, 2021

The Leaked NY Times Report and Digital Marketing for Medical Devices Are Closely Related

June 16, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?